Vaccine Info

AADvac1 Alzheimer's Disease Vaccine

Last Reviewed
January 8, 2021

AADvac1 Alzheimer's Disease Description

AADvac1 is a candidate therapeutic vaccine for Alzheimer's disease that targets misfolded tau protein, a common denominator of neurofibrillary pathology.

The AADvac1 vaccine consists of a synthetic peptide derived from amino acids 294 to 305 of the tau sequence, i.e., KDNIKHVPGGGS, coupled to keyhole limpet hemocyanin; the precise molecular nature of the antigen has not been disclosed.

AADvac1 uses aluminum hydroxide as an adjuvant.

AADvac1 Alzheimer's Disease Indication

AADvac1 is indicated as an active immunotherapy vaccine candidate for patients with diagnosed Alzheimer's disease (AD)

AADvac1 Alzheimer's Disease Dosage

Patients will receive 3 - 6 immunization doses.

AADvac1 Alzheimer's Disease Clinical Trials

Clinical Trial NCT01850238: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease (Completed)

  • AADvac1 is a candidate therapeutic vaccine for Alzheimer's disease that targets misfolded tau protein, a common denominator of neurofibrillary pathology.
  • Based on preclinical results, the intervention is expected to reduce the number of neurofibrillary tangles, remove hyperphosphorylated tau protein and reduce the amount of oligomerized and insoluble pathological tau in the brain, to halt the spread of neurofibrillary pathology through the brain, and thus prevent associated cognitive decline.
  • The vaccine's antigenic determinant is a synthetic peptide derived from a tau protein sequence coupled to keyhole limpet hemocyanin (KLH) and uses aluminum hydroxide (Alhydrogel) as an adjuvant.
  • At present, AADvac1 is intended as an active immunotherapy for patients with diagnosed Alzheimer's disease (AD). Patients will receive 3 - 6 immunization doses; the raised titers of therapeutic antibodies and possible benefits of the treatment can extend beyond the study's duration.
  • Because of the central role of pathological misfolded tau protein in AD's etiology, the vaccine is expected to be more effective than active or passive immunotherapies aiming to eliminate the amyloid β plaques that have been clinically investigated so far.

Clinical Trial NCT02031198: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (FUNDAMANT) (Completed)

  • AADvac1 is a candidate therapeutic vaccine for Alzheimer's disease that targets misfolded tau protein, a common denominator of neurofibrillary pathology. Based on preclinical results, the intervention is expected to reduce the number of neurofibrillary tangles, remove hyperphosphorylated tau protein and reduce the amount of oligomerized and insoluble pathological tau in the brain, to halt the spread of neurofibrillary pathology through the brain, and thus prevent associated cognitive decline.
  • The vaccine's antigenic determinant is a synthetic peptide derived from a tau protein sequence coupled to keyhole limpet hemocyanin (KLH) and uses aluminum hydroxide (Alhydrogel) as an adjuvant.
  • At present, AADvac1 is intended as an active immunotherapy for patients with diagnosed Alzheimer's disease (AD). According to need, patients will receive additional immunization doses beyond those administered in the preceding phase 1 trial; the raised titers of therapeutic antibodies and possible benefits of the treatment can extend beyond the study's duration.
  • Because of the central role of pathological misfolded tau protein in AD's etiology, the vaccine is expected to be more effective than active or passive immunotherapies aiming to eliminate the amyloid β plaques that have been clinically investigated so far.

Clinical Trial NCT02579252: 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (ADAMANT) (Active)

  • Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder of the brain. Over the course of the disease, pathological proteins accumulate in the brain, damaging neurons, thus causing them to lose their connections and die.
  • Currently, available treatments are designed to compensate for the neurotransmitter loss caused by the disease without affecting the disease process itself.
  • AADvac1 is designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology in AD). These antibodies are expected to prevent tau protein from aggregating, facilitate the removal of tau protein aggregates, and prevent the spreading of pathology, slowing or halting the disease's progress.